Antibody-drug conjugates (ADCs) are one of the rapidly growing classes of the biopharmaceutical market and formed by the conjugation of various drug species to a monoclonal antibody. Effective characterization methods for ADCs are needed to ensure the stability and efficacy of the drug because the complexity and heterogeneity of the ADC structure itself increase the process of linking the payload to the protein backbone.
Key learning points:
Speaker
Do-young Choi
Senior Field Application & Market Development Specialist, SCIEX Korea
Ye-Ji Kim
Field Application & Market Development Specialist, SCIEX Korea